Argent BioPharma Limited announced Dr. Shlomo Sadoun has joined Argent BioPharma's advisory board with immediate effect. Dr. Shlomo Sadoun has over 18 years of experience in the pharmaceutical sector. Dr. Sadoun co-founded and leads SK-Pharma Group, a global pharmaceutical company operating in 18 countries.

SK-Pharma specialises in producing and marketing generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical Additionally, Dr. Sadoun serves as the CEO of Arphio, an orphan drug company utilising proprietary technology to promote, market, and sell orphan drugs worldwide. Dr. Sadoun's expertise lies in leveraging technology to redefine business processes. He has established strategic alliances with over 200 innovative companies and launched more than 300 products globally, many of which were pioneering and branded.

Dr. Sadoun's adeptness in utilising technological advancements has propelled SK-Pharma to become the fastest-growing pharmaceutical group in Israel and beyond. Dr. Sadoun holds a master's degree in Global Management from Salford University and a Doctorate in Business Administration from the Royal Academy of Economics and Technology in Switzerland, with a focus on public health.